Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: Single institutional study

Hwa Jung Sung, Seok Jin Kim, Hee Yun Seo, Hye Ryoung Sul, Jong Gwon Choi, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin]. Fifty-two patients were enrolled in the study. The overall response rate was 63.5%. The median progression-free survival (PFS) and median overall survival (OS) was 18.0 and 39.5 months respectively. The most common toxicity was neutropenia. The factors related to poor outcome were a high International Prognostic Index (IPI) and a high 'B' score (bone marrow involvement, B symptoms, bulky disease). We developed a new prognostic model, namely the Prognostic Group for T cell NHL (PGT) that included four groups: PGT1 (low IPI/low B score), PGT2 (low IPI/high B score), PGT3 (high IPI/Low B score) and PGT4 (high IPI/Low B score). OS and PFS (not reached, 48 months) in the PGT1 group were significantly longer than those (11.5 and 4.8 months) in PGT2. The same result was observed in the PGT3 and PGT4 groups. The CEOP-B regimen was moderately active and tolerable for T-cell NHL patients, and the PGT system might be useful for the prediction of long-term survival of T-cell NHL patients.

Original languageEnglish
Pages (from-to)45-53
Number of pages9
JournalBritish Journal of Haematology
Volume134
Issue number1
DOIs
Publication statusPublished - 2006 Jul 1

Fingerprint

T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Doxorubicin
Disease-Free Survival
Survival
Epirubicin
Bleomycin
Vincristine
Prednisone
Neutropenia
Cyclophosphamide
Bone Marrow
Prospective Studies

Keywords

  • Chemotherapy
  • Prognosis factor
  • T-cell non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

@article{8aa93ec87cfc40239cc864f0b499bd0b,
title = "Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: Single institutional study",
abstract = "The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin]. Fifty-two patients were enrolled in the study. The overall response rate was 63.5{\%}. The median progression-free survival (PFS) and median overall survival (OS) was 18.0 and 39.5 months respectively. The most common toxicity was neutropenia. The factors related to poor outcome were a high International Prognostic Index (IPI) and a high 'B' score (bone marrow involvement, B symptoms, bulky disease). We developed a new prognostic model, namely the Prognostic Group for T cell NHL (PGT) that included four groups: PGT1 (low IPI/low B score), PGT2 (low IPI/high B score), PGT3 (high IPI/Low B score) and PGT4 (high IPI/Low B score). OS and PFS (not reached, 48 months) in the PGT1 group were significantly longer than those (11.5 and 4.8 months) in PGT2. The same result was observed in the PGT3 and PGT4 groups. The CEOP-B regimen was moderately active and tolerable for T-cell NHL patients, and the PGT system might be useful for the prediction of long-term survival of T-cell NHL patients.",
keywords = "Chemotherapy, Prognosis factor, T-cell non-Hodgkin lymphoma",
author = "Sung, {Hwa Jung} and Kim, {Seok Jin} and Seo, {Hee Yun} and Sul, {Hye Ryoung} and Choi, {Jong Gwon} and Choi, {In Keun} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Choi, {Chul Won} and Kim, {Byung Soo} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2006",
month = "7",
day = "1",
doi = "10.1111/j.1365-2141.2006.06124.x",
language = "English",
volume = "134",
pages = "45--53",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B

T2 - Single institutional study

AU - Sung, Hwa Jung

AU - Kim, Seok Jin

AU - Seo, Hee Yun

AU - Sul, Hye Ryoung

AU - Choi, Jong Gwon

AU - Choi, In Keun

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin]. Fifty-two patients were enrolled in the study. The overall response rate was 63.5%. The median progression-free survival (PFS) and median overall survival (OS) was 18.0 and 39.5 months respectively. The most common toxicity was neutropenia. The factors related to poor outcome were a high International Prognostic Index (IPI) and a high 'B' score (bone marrow involvement, B symptoms, bulky disease). We developed a new prognostic model, namely the Prognostic Group for T cell NHL (PGT) that included four groups: PGT1 (low IPI/low B score), PGT2 (low IPI/high B score), PGT3 (high IPI/Low B score) and PGT4 (high IPI/Low B score). OS and PFS (not reached, 48 months) in the PGT1 group were significantly longer than those (11.5 and 4.8 months) in PGT2. The same result was observed in the PGT3 and PGT4 groups. The CEOP-B regimen was moderately active and tolerable for T-cell NHL patients, and the PGT system might be useful for the prediction of long-term survival of T-cell NHL patients.

AB - The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin]. Fifty-two patients were enrolled in the study. The overall response rate was 63.5%. The median progression-free survival (PFS) and median overall survival (OS) was 18.0 and 39.5 months respectively. The most common toxicity was neutropenia. The factors related to poor outcome were a high International Prognostic Index (IPI) and a high 'B' score (bone marrow involvement, B symptoms, bulky disease). We developed a new prognostic model, namely the Prognostic Group for T cell NHL (PGT) that included four groups: PGT1 (low IPI/low B score), PGT2 (low IPI/high B score), PGT3 (high IPI/Low B score) and PGT4 (high IPI/Low B score). OS and PFS (not reached, 48 months) in the PGT1 group were significantly longer than those (11.5 and 4.8 months) in PGT2. The same result was observed in the PGT3 and PGT4 groups. The CEOP-B regimen was moderately active and tolerable for T-cell NHL patients, and the PGT system might be useful for the prediction of long-term survival of T-cell NHL patients.

KW - Chemotherapy

KW - Prognosis factor

KW - T-cell non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33744811464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744811464&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2006.06124.x

DO - 10.1111/j.1365-2141.2006.06124.x

M3 - Article

C2 - 16803566

AN - SCOPUS:33744811464

VL - 134

SP - 45

EP - 53

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -